An Open Phase II, Multi Center Trial of BAY 59-8862 in Patients With Aggressive, Refractory Non-Hodgkin's Lymphoma
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Bayer Study Director
Study Director
Bayer
United States: Food and Drug Administration
100389
NCT00044551
February 2002
July 2003
Name | Location |
---|---|
Hinsdale, Illinois 60521 | |
Miami, Florida 33176 | |
Albany, New York 12208 | |
Cleveland, Ohio 44195 | |
Nashville, Tennessee 37203-1632 | |
Seattle, Washington 98195 | |
Hackensack, New Jersey 07601 | |
Metairie, Louisiana 70006 | |
Milwaukee, Wisconsin |